ClinicalTrials.gg
CompletedNCT00002436Updated Jun 24, 2005

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

A Phase 3 interventional study of Lamivudine and Zidovudine in HIV Infections, sponsored by Glaxo Wellcome. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
35th of 126
325 · median 154
Phase 3
50 of 132
2 open now
Registered
1st of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is the 35th largest by enrollment of the 126 interventional ones that give a count, is one of 50 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.

PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.

Read the detailed description

Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52 weeks.

PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.

03

Conditions studied

  • HIV Infections

Keywords

  • Zalcitabine
  • Drug Therapy, Combination
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Antiviral Agents
  • Zidovudine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • positivity.
  • 100-300 cells/mm3.
  • Prior AZT therapy for 24 or more weeks and currently on AZT.

Exclusion criteria

Exclusion Criteria

Patients with the following prior conditions are excluded:

  • History of intolerance to AZT.
  • History of grade 2 or worse peripheral neuropathy.

Prior Medication:

Excluded:

  • Any prior antiretroviral therapy other than AZT.

Required:

  • Concomitant AZT therapy.

Required:

  • At least 24 weeks of prior AZT.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
325 participants

Interventions

06

Study locations

22 sites
  • Combat Group
    Los Angeles, California 90028, United States
  • San Diego Community Research Group
    San Diego, California 92104, United States
  • ViRx Inc
    San Francisco, California 94103, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Chicago Ctr for Clinical Research
    Chicago, Illinois 60607, United States
  • Louisiana Cardiovascular Research Ctr
    New Orleans, Louisiana 70119, United States
  • Boston City Hosp / FGH-1
    Boston, Massachusetts 02118, United States
  • Nassau County Med Ctr
    East Meadow, New York 11554, United States
  • Saint Luke's - Roosevelt Hosp Ctr
    New York, New York 10019, United States
  • Nalle Clinic
    Charlotte, North Carolina 28207, United States
  • Duke Univ Med Ctr
    Durham, North Carolina 27710, United States
  • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    Portland, Oregon 97210, United States
  • Milton S Hershey Med Ctr
    Hershey, Pennsylvania 17033, United States
  • Central Texas Med Foundation
    Austin, Texas 78751, United States
  • Univ of Texas Southwestern Med Ctr of Dallas
    Dallas, Texas 75235, United States
  • Nicholaos Bellos
    Dallas, Texas 75246, United States
  • Houston Clinical Research Network
    Houston, Texas 77006, United States
  • Wisconsin Community - Based Research Consortium
    Milwaukee, Wisconsin 53202, United States
  • Ottawa General Hospital
    Ottawa, Ontario, Canada
  • Toronto Hosp
    Toronto, Ontario, Canada
  • Montreal Gen Hosp
    Montreal, Quebec, Canada
  • Hosp Regional de Ponce - Area Vieja
    Ponce, 00731, Puerto Rico
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002436
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 1994. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamivudine

Start the discussion